Drugs / PLACULUMAB
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01240876 | Jan 2011 → Mar 2013 | sciatica | Cephalon | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00928317 | Apr → Nov 2009 | rheumatoid arthritis | Arana Therapeutics Ltd | Terminated | No outcome recorded |
| Phase 2 | NCT00854685 | Feb → Dec 2009 | rheumatoid arthritis | Arana Therapeutics Ltd | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PLACULUMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108739 ↗ |
| Known as | ART-621 ( ANTI-TUMOUR NECROSIS FACTOR ALPHA ANTIBODY) | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108739 ↗ |
| Known as | ART621 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00928317 ↗ |
| Known as | CEP-37247 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01240876 ↗ |
| Known as | PN-0621 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108739 ↗ |
| Action | Inhibit | “ART621 is an anti-TNF molecule” NCT00854685 ↗ |
| Modality | Protein / enzyme biologic | “ART621 is an anti-TNF molecule that contains 2 identical domain "antibodies" that have the binding activity of a full antibody” NCT00854685 ↗ |
| Route | Intravenous | “ART621 when administered with an intravenous loading dose followed by subcutaneous administration every week compared to every fortnight” NCT00854685 ↗ |
| Route | Subcutaneous | “ART621 when administered with an intravenous loading dose followed by subcutaneous administration every week compared to every fortnight” NCT00854685 ↗ |
| Target | TNF | “ART621 is an anti-TNF molecule” NCT00928317 ↗ |